You are here

BCRF Grantee Since


Donor Recognition

The ULTA Beauty Award

Area(s) of Focus

Lyndsay N. Harris, MD

Diana Hyland Chair in Breast Cancer
Director, Breast Cancer Program
Professor of Medicine
Division of Hematology and Oncology
University Hospitals - Seidman Cancer Center
Case Western Reserve University School of Medicine
Cleveland, Ohio

Current Research

Determining which breast cancer patients receive the most benefit from targeted therapy is critical to the success of personalized medicine. The focus of Dr. Harris’s BCRF research is to identify biomarkers in the tumor tissue or blood of patients that can be used to predict which patients will benefit from a particular therapy. She uses many approaches including genomics (measuring the specific patterns of gene mutations and expression), proteomics (measuring patterns of proteins) and has recently developed techniques to grow a patient’s tumor under laboratory conditions to study how tumors behave in response to specific therapies. With BCRF support, Dr. Harris’s laboratory has discovered several biomarkers that may someday be used to identify the best therapy for breast cancer and ultimately both improve cure rates and reduce toxicity from unnecessary treatment. In the coming year they will validate these findings in a prospective clinical trial.


Dr. Harris' research has focused on the development of biomarkers and targeted therapeutics to improve outcome for breast cancer patients. Her laboratory uses genomic technologies to develop breast cancer signatures that can be used to optimize selection for therapy. She is Director of the Seidman Breast Cancer Program at UH/Case Western Reserve with 20 years experience as a clinician, clinical-trialist and translational researcher. She has published more than 100 scientific research articles and made contributions to the understanding of the molecular subtypes of breast cancer and the implication of gene, gene expression, and protein expression profiles on treatment response and resistance. She serves on a variety of national and international committees for American Society of Clinical Oncology (ASCO), Cancer and Leukemia B (CALGB), Eastern Cooperative Oncology Group (ECOG), Pan American Cancer Trials Network, (Neo) ALTTO International Adjuvant Breast Cancer Clinical Trial and Novartis and serves on scientific review committees for the U.S. Department of Defense, Komen Breast Cancer Foundation, National Cancer Institute and ASCO. Her career goal is to help patients by better understanding biomarkers of response and resistance to therapy to make better choices when selecting treatment for breast cancer.